Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma

Figure 1

CT imaging prior to nivolumab/ipilimumab treatment: (a) axial imaging demonstrating the heterogeneously enhancing left renal mass; (b) coronal imaging demonstrating the enlarged retroperitoneal lymphadenopathy.

(a)

(b)